DIANTHUS THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.22 USD | -4.65% |
|
-12.64% | +142.50% |
| Jul. 01 | Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Small Cap Comp Value Index | CI |
| Jul. 01 | Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Small Cap Completeness Index | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 154.1 | 828.5 | - | - |
| Enterprise Value (EV) 1 | -19.61 | 515 | 310 | 828.5 |
| P/E ratio | -1.23 x | -12.8 x | -10.7 x | -8.68 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 54.5 x | 501 x | 473 x | 306 x |
| EV / Revenue | -6.94 x | 312 x | 177 x | 306 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | 0.53 x | -6.6 x | -3.2 x | -7.34 x |
| FCF Yield | 188% | -15.1% | -31.3% | -13.6% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 14,818 | 29,349 | - | - |
| Reference price 2 | 10.40 | 28.23 | 28.23 | 28.23 |
| Announcement Date | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 2.826 | 1.653 | 1.752 | 2.707 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -48.17 | -78.91 | -100 | -130 |
| Operating Margin | - | -1,704.67% | -4,773.91% | -5,709.3% | -4,802.42% |
| Earnings before Tax (EBT) 1 | - | -43.56 | -63.93 | -89.06 | -120.8 |
| Net income 1 | -28.48 | -43.56 | -63.93 | -89.06 | -120.8 |
| Net margin | - | -1,541.22% | -3,867.74% | -5,083.84% | -4,462.44% |
| EPS 2 | -7.100 | -8.450 | -2.198 | -2.636 | -3.252 |
| Free Cash Flow 1 | - | -36.97 | -78 | -96.9 | -112.8 |
| FCF margin | - | -1,308.24% | -4,718.69% | -5,531.34% | -4,167.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/1/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.924 | 0.457 | 0.874 | 0.2689 | 0.2689 | 0.2689 | 0.2392 | 0.2392 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -15.76 | -12.96 | -17.84 | -18.95 | -20.33 | -21.8 | -21.37 | -22.38 |
| Operating Margin | -1,705.52% | -2,835.01% | -2,041.65% | -7,046.53% | -7,563.31% | -8,108.84% | -8,931.66% | -9,354.65% |
| Earnings before Tax (EBT) 1 | -14.76 | -10.56 | -13.75 | -14.99 | -16.46 | -18.75 | -16.95 | -18.67 |
| Net income 1 | -14.76 | -10.56 | -13.75 | -14.99 | -16.46 | -18.75 | -16.95 | -18.67 |
| Net margin | -1,597.73% | -2,311.38% | -1,573% | -5,574.7% | -6,121.4% | -6,975.01% | -7,084.92% | -7,802.3% |
| EPS 2 | -3.780 | - | -0.5400 | -0.5450 | -0.5925 | -0.6500 | -0.6000 | -0.6700 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/23 | 3/21/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 174 | 314 | 519 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -37 | -78 | -96.9 | -113 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.11 | 0.14 | 0.16 | 0.19 |
| Capex / Sales | - | 3.89% | 8.44% | 9.19% | 7.07% |
| Announcement Date | 8/1/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.23
USD
Average target price
48.75
USD
Spread / Average Target
+72.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +142.50% | 829M | |
| +18.43% | 124B | |
| +19.81% | 114B | |
| -23.74% | 19.42B | |
| -18.00% | 16.2B | |
| -19.97% | 15.31B | |
| -49.33% | 14.19B | |
| +57.08% | 14.32B | |
| +7.95% | 14.31B | |
| +126.04% | 11.29B |
- Stock Market
- Equities
- DNTH Stock
- Financials Dianthus Therapeutics, Inc.
